Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

Brent N. Rexer, Jeffrey A. Engelman, Carlos L. Arteaga

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Tyrosine kinase inhibitors (TKIs) are effective anti-cancer therapies but resistance to these agents eventually develops. Several models of resistance to TKIs have been studied including resistance to EGFR inhibitors. Recent studies in EGFR-dependent A431 cells found upregulation of the IGF1R pathway as a mechanism to overcome blockade of EGFR. This was associated with amplification of IGF1R signaling and recovery of downstream PI3K-AKT activation. This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients. In this review, these model systems and their applicability to human cancers, as well as strategies to identify and overcome resistance to TKIs, are discussed.

Original languageEnglish (US)
Pages (from-to)18-22
Number of pages5
JournalCell Cycle
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2009

Keywords

  • Breast cancer
  • EGFR
  • HER2
  • PI3K
  • TKI resistance
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists'. Together they form a unique fingerprint.

  • Cite this